title: Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
abstract: BACKGROUND
  Cancer-associated hypercalcemia (CAH) is the most frequent metabolic disorder in cancer patients. We retrospectively reviewed the outcome and prognostic factors for patients with CAH being treated with standard intravenous disphosphonates.
  
  
  METHODS
  Two hundred sixty patients were reviewed. Overall survival and prognostic factors were analyzed. Relative risks (RR) for early death (within 60 days) were assessed (Fischer exact test and logistic regression model).
  
  
  RESULTS
  Median survival was 64 days (range, 12-1,955+). Multivariate analysis identified the following factors as poor survival predictors: serum corrected calcium >2.83 mmol/l [hazard ratio (HR) = HR 2.21], albuminemia <35.5 (HR 2.41), squamous cell carcinoma (HR 2.64), bone metastasis (HR 1.44), and liver metastasis (HR 2..22). One hundred twenty-one patients died within 60 days. For those patients, the logistic regression model identified four independent predicting factors for early death: calcemia >2.83 mmol/l (RR 5.07), hypoalbuminemia (RR 7.42), liver metastasis (RR 4.34), and squamous cell carcinomas (RR 2.21).
  
  
  CONCLUSIONS
  Despite intravenous diphosphonate, CAH is still associated with poor outcome. Simple bedside parameters may estimate the risk of early deaths.
authors: Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France. n-penel@o-lambret.fr
authors: Nicolas
authors: N
authors: Penel
authors: Sylvain
authors: S
authors: Dewas
authors: Philippe
authors: P
authors: Doutrelant
authors: Stéphanie
authors: S
authors: Clisant
authors: Yazdan
authors: Y
authors: Yazdanpanah
authors: Antoine
authors: A
authors: Adenis
mesh_terms: D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
references: Br J Cancer. 1994 Jul;70(1):169-72
references: 8018531
references: J Clin Oncol. 1986 Aug;4(8):1177-83
references: 3016205
references: Lancet. 1993 Jun 26;341(8861):1611-3
references: 8099988
references: Am J Med. 1993 Sep;95(3):297-304
references: 8368227
references: Br J Cancer. 1995 Jul;72(1):206-9
references: 7599053
references: J Cancer Res Clin Oncol. 1994;120(10):610-4
references: 7929533
references: Oral Oncol. 2005 Oct;41(9):884-9
references: 16043379
references: Medicine (Baltimore). 1980 Jul;59(4):262-82
references: 6993843
references: J Clin Gastroenterol. 1987 Feb;9(1):78-82
references: 3559119
references: J Clin Oncol. 2005 Dec 20;23(36):9219-26
references: 16275935
references: J Clin Oncol. 2001 Jan 15;19(2):558-67
references: 11208851
references: Am J Med. 2003 Aug 1;115(2):115-21
references: 12893397
references: J Intern Med. 1998 Sep;244(3):189-98
references: 9747741
references: Annu Rev Med. 1994;45:189-200
references: 8198376
references: Urology. 1989 Mar;33(3):167-70
references: 2521966
references: Cancer Chemother Rep. 1966 Mar;50(3):163-70
references: 5910392
references: Ann Intern Med. 1990 Apr 1;112(7):499-504
references: 2138442
references: Bull Cancer. 1995 Nov;82(11):975-80
references: 8535025
references: Cancer. 1978 Jun;41(6):2276-85
references: 657092
references: Cancer. 1994 Apr 15;73(8):2223-30
references: 8156530
references: J Clin Pathol. 1979 Jan;32(1):56-60
references: 429580
references: J Urol. 1991 Feb;145(2):248-50
references: 1988711
references: Cancer J. 2006 Jan-Feb;12 (1):47-53
references: 16613662
references: Cancer. 2000 Jun 15;88(12 Suppl):2961-78
references: 10898340
references: Acta Oncol. 1990;29(5):577-80
references: 2206569